STAT+: Drug Meant to Make Gene Therapy Safer May Also Make It Less Effective

Why It Matters

If immune‑suppressants like sirolimus compromise efficacy, developers must balance safety with therapeutic outcomes, potentially reshaping dosing strategies across the gene‑therapy sector.

Key Takeaways

• Encoded trial enrolled 21 Dravet syndrome children, using steroids.
• High-dose cohort also received sirolimus, a transplant anti-rejection drug.
• Sirolimus appeared to dampen gene therapy's therapeutic effect.
• Findings raise safety‑efficacy trade‑offs for gene‑therapy developers.
• Companies like Sarepta may need to reassess immune‑suppression protocols.

Pulse Analysis

Gene‑therapy’s promise hinges on delivering functional DNA without triggering the body’s defenses. To date, most programs rely on corticosteroids to temper the innate immune response to viral vectors, a strategy that has become standard in trials for neurological disorders. Sirolimus, an mTOR inhibitor traditionally used in organ transplantation, has recently been added to the armamentarium for its potent anti‑rejection properties, raising hopes of even greater protection against vector‑induced inflammation.

Encoded Therapeutics’ recent Dravet syndrome study, however, flags a potential downside. In the high‑dose arm where children received both steroids and sirolimus, investigators recorded a measurable decline in the expected seizure‑reduction outcomes. The hypothesized mechanism involves sirolimus’ broad suppression of cellular proliferation, which may inadvertently limit the transduction efficiency of adeno‑associated viruses and dampen expression of the therapeutic gene. While the sample size remains modest, the signal is strong enough to prompt a re‑examination of dosing schedules and combination regimens.

The broader industry impact could be significant. Companies such as Sarepta and Regenxbio, which embed immune‑modulation into their gene‑therapy pipelines, may need to revisit safety protocols to avoid compromising efficacy. Regulators might also demand more granular data on the interplay between immunosuppression and vector performance. Ultimately, the findings underscore the delicate balance between mitigating adverse immune reactions and preserving the therapeutic payload, a challenge that will shape next‑generation gene‑therapy design and clinical trial architecture.